当前位置: 首页 >> 检索结果
1. Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy.
作者: Samuel Luebbe.;Allan D Sniderman.;Andrew E Moran.;John T Wilkins.;Ciaran N Kohli-Lynch.
来源: JAMA. 2026年
Apolipoprotein B (apoB) is a superior marker of residual atherosclerotic cardiovascular disease risk in patients treated with lipid-lowering therapy (LLT) compared with low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). The cost-effectiveness of LDL-C, non-HDL-C, and apoB goals has not been established.
5. Discontinuation of Levothyroxine in Adults Aged 60 Years or Older.
作者: Janneke Ravensberg.;Jacobijn Gussekloo.;Saskia Le Cessie.;Olaf M Dekkers.;Simon P Mooijaart.;Rosalinde K E Poortvliet.
来源: JAMA. 2026年
Many adults aged 60 years or older take the thyroid hormone levothyroxine, which is generally continued for life. However, it is uncertain whether long-term continuation is always necessary.
7. Does This Child Have a Concussion?: The Rational Clinical Examination Systematic Review.
Concussion is a mild traumatic brain injury with associated abnormalities in brain function, rather than structural injury. An estimated 1.1 million to 1.9 million pediatric concussions occur annually in the US.
13. Changes in Clinician Time Expenditure and Visit Quantity With Adoption of Artificial Intelligence-Powered Scribes: A Multisite Study.
作者: Lisa S Rotenstein.;A Jay Holmgren.;Robert Thombley.;Aditi Sriram.;Reema H Dbouk.;Melissa Jost.;Debbie Aizenberg.;Scott MacDonald.;Naga Kanaparthy.;Brian Williams.;Allen Hsiao.;Lee Schwamm.;Sara Murray.;Maria Byron.;Jacqueline G You.;Amanda J Centi.;Christine Iannaccone.;Michelle Frits.;Adam B Landman.;Karandeep Singh.;Ming Tai-Seale.;Jie Cao.;Katharine Lawrence.;Devin Mann.;Christopher Holland.;Bryan Blanchette.;Jesse Ehrenfeld.;Edward R Melnick.;David W Bates.;Julia Adler-Milstein.;Rebecca G Mishuris.
来源: JAMA. 2026年
Artificial intelligence (AI)-enabled scribes have been proposed to reduce electronic health record (EHR) burden and improve clinician satisfaction. There is limited evidence about their associated results across multiple sites and relative benefits for different clinician groups.
17. Lead-Attributable Cardiovascular Disease Burden: Global Burden of Disease Study 2023.
作者: .;Jeffrey D Stanaway.;Sandra Spearman.;Nicole K DeCleene.;Vanessa Garcia.;Laura Lara-Castor.;Stephen S Lim.;Christopher J L Murray.;Gregory A Roth.;Matthew A Seymour.;Benjamin Stark.;Michael Brauer.
来源: JAMA. 2026年
Despite declines, lead exposure remains a major risk factor for cardiovascular disease (CVD) mortality. Quantifying the direct effects of cumulative bone lead exposure on CVD is essential to guide prevention and policy.
20. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
作者: Nicholas A Marston.;Erin A Bohula.;Ajay K Bhatia.;Gaetano M De Ferrari.;Lawrence A Leiter.;Jose C Nicolau.;Jeong-Gun Park.;Sabina A Murphy.;Emileigh Walsh.;Lyrica Liu.;Subodh Verma.;Naveed Sattar.;Stephen J Nicholls.;Jose Lopez-Sendon.;Ioanna Gouni-Berthold.;Lale Tokgozoglu.;Ron Blankstein.;Marcoli Cyrille.;Gabriel Paiva da Silva Lima.;Robert P Giugliano.;Marc S Sabatine.; .
来源: JAMA. 2026年
Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis.
|